A 43-year-old female patient diagnosed with advanced non-small cell lung cancer with bone metastasis harbored the EGFR exon 19 deletion and received the treatment of erlotinib, and the mass of the right lung tumor was reduced after about 2 months of treatment. This evidence concerns the gene EGFR and bone metastasis.